Full Breakdown
Acetaminophen Use During Pregnancy: New Insights from Taiwan Study
3/10/2026, 10:58:28 AM
Overview of the Study's Findings
A recent nationwide cohort study conducted in Taiwan has reignited the debate surrounding the potential link between maternal acetaminophen prescriptions during pregnancy and neurodevelopmental disorders in offspring, specifically attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The study analyzed data from over 2 million births between 2004 and 2015, revealing initial positive associations between prenatal acetaminophen exposure and increased risks of ADHD (hazard ratio [HR] 1.12) and ASD (HR 1.06). However, these associations became null when sibling-matched analyses were employed, indicating potential biases in the original findings.
Sibling-Matched Analysis and Bias Concerns
The sibling-matched analysis, which included more than 1.2 million children, aimed to control for confounding factors such as genetic and familial risks. Despite the null findings in sibling comparisons, the researchers noted a complex pattern: when only the older sibling was exposed to acetaminophen, there was a significant association with ADHD (HR 1.33) and ASD (HR 1.75). Conversely, when only the younger sibling was exposed, the associations reversed, suggesting unaddressed biases in the data. The authors concluded that these discrepancies warrant further investigation into the validity of sibling studies in this context.
Expert Opinions and Broader Context
Cynthia Gyamfi-Bannerman, MD, from the University of California San Diego Health, acknowledged the study's limitations, emphasizing that while the sibling analysis brought findings closer to null, unmeasured biases remain. This sentiment is echoed by other studies, including those from Sweden and Japan, which found that positive associations between acetaminophen and neurodevelopmental outcomes dissipated in sibling comparisons. Gyamfi-Bannerman noted, "I think that it's telling that all of these cohort studies... don't get to a causal relationship."
Implications of Political Discourse
The discourse surrounding acetaminophen use during pregnancy gained significant attention following a press conference by President Donald Trump, where he advised pregnant women against taking Tylenol, citing potential risks. This statement, despite lacking a solid scientific basis, influenced public perception and prescribing practices. A study indicated that prescriptions for acetaminophen dropped by approximately 10% following the press conference, while prescriptions for leucovorin, a proposed treatment for autism-related speech deficits, surged.
Conflicting Reports and Ongoing Debate
While the Taiwanese study aligns with previous research indicating that the association between acetaminophen and neurodevelopmental disorders may be confounded by other factors, it also raises questions about the reliability of sibling studies. Experts like Viktor Ahlqvist, involved in the Swedish sibling study, noted that the Taiwanese findings do not invalidate previous results but suggest the need for caution in interpreting sibling study outcomes. Yusuke Okubo, a co-author of the Japanese study, echoed this caution, stating that ruling out potential harm based solely on sibling studies is premature.
Conclusion: The Need for Continued Research
The ongoing debate about the safety of acetaminophen during pregnancy highlights the complexities of observational research. While the Taiwanese study adds to the body of evidence suggesting that the drug does not cause ADHD or ASD, it also underscores the challenges of drawing firm conclusions from large datasets. As the scientific community continues to explore this issue, it remains essential for healthcare providers to balance the need for effective pain management during pregnancy with the evolving understanding of potential risks.
